The Effect of Cisplatin+Pemetrexed Chemotherapy Combined with Osimertinib Targeted Therapy on EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer

OU Xianhui; HE Fumei; HU Wanying

doi:10.3969/j.issn.1672-7185.2025.12.012

Abstract：Objective Investigation of the efficacy of cisplatin+pemetrexed chemotherapy combined with osimertinib for epidermal growth factor receptor(EGFR)mutation-positive non-small cell lung cancer(NSCLC).Methods One hundred of EGFR mutation positive NSCLC patients from May 2017 to July 2023 at Nanping First Hospital affiliated to Fujian Medical University were retrospectively collected.They were divided into a conventional group of 49 patients(receiving cisplatin+pemetrexed chemotherapy)and a study group of 51 patients(receiving cisplatin+pemetrexed chemotherapy combined with osimertinib)according to different treatment plans.The treatment efficacy and changes in tumor markers between two groups were compaerd.Results The disease control rate and objective remission rate of the research group were 82.35%and 45.10%,respectively,which were higher than the conventional group's 61.22%and 24.49%(P<0.05).The serum levels of cytokeratin 19 fragment,carcinoembryonic antigen,and squamous cell carcinoma antigen in the study group were lower than those in the control group(P<0.05).There was no statistically significant difference in the incidence of diarrhea,fatigue,nausea and vomiting,leukopenia,transaminase abnormalities,and rash between the two groups(P>0.05).The median progression free survival time for the study group and the control group was 13.5 months and 10.5 months,respectively,the median survival times were 17.5 months and 14.0 months,and the Log rank test showed no statistically significant difference between the groups(P>0.05).Conclusion The combination therapy of cisplatin+pemetrexed chemotherapy and osimertinib can further reduce the expression of tumor markers and improve the short-term therapeutic effect of EGFR mutation positive NSCLC.